Jeremy Schreiber,

MSN, PMHNP-BC

Jeremy Schreiber

MSN, PMHNP-BC

Founder, CEO, and Psychiatric-Mental Health Nurse Practitioner Prescriber, Enlighten Health Care

Jeremy Schreiber,

MSN, PMHNP-BC

Founder, CEO, and Psychiatric-Mental Health Nurse Practitioner Prescriber, Enlighten Health Care

Jeremy Schreiber is a healthcare professional with a strong focus on mental health. Currently serving as adjunct faculty for West Liberty University in West Liberty, West Virginia, Jeremy is also a clinical preceptor for numerous educational institutions across the nation. Dedicated to the advancement of mental health care, he obtained his Master of Science in Nursing degree from Ohio State University, and he is a current member of the Mental Health Working Group for the Alliance for Patient Access and the TD Expert Panel for the CureSZ foundation. Jeremy is the Founder and CEO of Enlighten Health Care, LLC, a leading healthcare organization based in Wheeling, West Virginia, where he actively practices as a Psychiatric-Mental Health Nurse Practitioner.

Jeremy's Shared Resources

Study Reveals Comorbidities and Outcomes in Psychiatric Inpatients With Tardive Dyskinesia: Implications for Severe Illness and Healthcare Costs

Researchers of a study analyzed comorbidities and outcomes in psychiatric inpatients with tardive dyskinesia (TD). The study used a case-control...
CURATED BY:
Jeremy Schreiber,
MSN, PMHNP-BC

Study Reveals Why Black Americans Face Higher Tardive Dyskinesia Risk

A study shows the increased risk of tardive dyskinesia (TD) among Black individuals in the United States compared with White...
CURATED BY:
Jeremy Schreiber,
MSN, PMHNP-BC

Patient Questions in Identifying and Screening for Tardive Dyskinesia

Access a quiz on tardive dyskinesia (TD) based on an insightful interview with Amber Hoberg, MSN, APRN, PMHNP-BC. Learn more...
CURATED BY:
Jeremy Schreiber,
MSN, PMHNP-BC

Study Finds Patient Perception of Tardive Dyskinesia’s Impact Differs From Clinician Assessment

Researchers of a study examined the impact of tardive dyskinesia (TD) patient health and social functioning, conducted in two cohorts:...
CURATED BY:
Jeremy Schreiber,
MSN, PMHNP-BC

Link Between Antidepressants and Tardive Dyskinesia Explored

In a recent study, researchers critiqued various reviews and case reports associating non-dopamine-receptor-blocking drugs (DRBDs) with a tardive dyskinesia (TD)...
CURATED BY:
Jeremy Schreiber,
MSN, PMHNP-BC

Researchers Examine Effectiveness of VMAT2 Inhibitors in Treating Tardive Dyskinesia

Researchers of a study examined the effectiveness of vesicular monoamine transporter-2 (VMAT2) inhibitors and other agents in light of different...
CURATED BY:
Jeremy Schreiber,
MSN, PMHNP-BC
Share